Integrin-linked kinase (ILK): a "hot" therapeutic target

Area of Science:

• Cellular Biology
• Molecular Biology
• Oncology

Background:

• Integrin-mediated cell adhesion regulates gene expression via transcription factors.
• Integrin-linked kinase (ILK) is a serine-threonine kinase that interacts with integrin subunits.
• ILK modulates signaling pathways including Wnt, growth factor, and AP-1 signaling.

Purpose of the Study:

• To elucidate the role of ILK in integrin-mediated signaling.
• To investigate the relationship between ILK, PTEN, and PKB/Akt activation.
• To evaluate ILK as a therapeutic target in solid tumors.

Main Methods:

• Investigated ILK interactions with beta-catenin and LEF-1.
• Assessed ILK's effect on glycogen synthase kinase-3 (GSK-3) and activator protein-1 (AP-1) activity.
• Examined ILK's role in phosphatidylinositol 3-kinase (PI3K)/PKB/Akt signaling.
• Analyzed ILK activity in PTEN-mutant cells and the effect of an ILK inhibitor.

Main Results:

• ILK overexpression promotes beta-catenin nuclear translocation and LEF-1 transcriptional activity.
• ILK phosphorylates and inhibits GSK-3, stimulating AP-1 activity.
• ILK phosphorylates and activates PKB/Akt, acting upstream of PI3K.
• ILK activity is constitutively elevated in PTEN-mutant cells, and ILK inhibition reduces PKB/Akt phosphorylation at Ser-473.

Conclusions:

• ILK is a crucial regulator of integrin, growth factor, and Wnt signaling pathways.
• PTEN inactivation leads to constitutive PKB/Akt activation and elevated ILK activity.
• Targeting ILK with inhibitors may offer a valuable therapeutic strategy for solid tumors, particularly those with PTEN mutations.